A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multi

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Last Updated May 29, 2025

Want to learn how to participate in this trial?

CR109118

OVERVIEW

Sexes Eligible for Study
all
Age
18+ years
Phase
phase 2
Sites
60 Sites
Status

Recruiting

SUMMARY

The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.

CONDITIONS

Relapsed/Refractory Multiple Myeloma

ELIGIBILITY

Inclusion Criteria:

For Period 1, 2 and 3

* Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria
* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1
* Must not be pregnant or must not plan to become pregnant within the study period
* Participants must sign an informed consent form (ICF) indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection
* For Period 1 and 2: Received at least 3 prior lines of therapy (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). Undergone at least 1 complete cycle of treatment for each line of therapy, unless progressive disease (PD) was the best response to the line of therapy
* Must have documented evidence of progressive disease based on participating physician's determination of response by the IMWG response criteria on or after the last regimen. Participants with documented evidence of progressive disease within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are also eligible
* Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
* Period 1: Received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody (prior exposure can be from different monotherapy or combination regimens)
* Period 2: Received as part of previous therapy a PI, an IMiD, an anti-CD38 antibody, and BCMA-targeted therapy (prior exposure can be from different monotherapy or combination regimens)
* For period 3: Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level .5 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio

Inclusion Criteria:

For Period 1, 2 and 3

More...

DETAILS

LOCATIONS

Locations in:

Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom, Austria, Greece

Country (9)	City or Province (60)	Status
Belgium	Leuven UZ Leuven	COMPLETED
Belgium	Yvoir Ucl de Mont-Godinne	COMPLETED
France	Nantes Cedex 1 CHU de Nantes hotel Dieu	COMPLETED
France	Pierre-Bénite Centre hospitalier Lyon-Sud	COMPLETED
Germany	Berin Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin	RECRUITING
Germany	Dresden Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden	RECRUITING
Germany	Hamburg Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik	RECRUITING
Germany	Hamm St. Barbara-Klinik Hamm GmbH	RECRUITING
Germany	Heidelberg Universitaetsklinikum Heidelberg	RECRUITING
Germany	Koeln Universitaetsklinikum Koeln	RECRUITING
Germany	Leipzig Universitaetsklinikum Leipzig	RECRUITING
Germany	Tubingen Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany	RECRUITING
Germany	Wuerzburg Universitatsklinikum Wurzburg	RECRUITING
Italy	Bari U.O. Ematologia Istituto Tumori Giovanni Paolo II	COMPLETED
Italy	Genova IRCCS Azienda Ospedaliera San Martino - IST	COMPLETED
Italy	Roma Università di Roma La Sapienza	COMPLETED
Italy	San Giovanni Rotondo IRCCS Ospedale Casa Sollievo della Sofferenza	COMPLETED
Italy	Tricase Ospedale Cardinale G. Panico	COMPLETED
Netherlands	Amsterdam VU Medisch Centrum	COMPLETED
Netherlands	Groningen UMCG	COMPLETED
Spain	Barcelona Inst. Cat. Doncologia-H Duran I Reynals	COMPLETED
Spain	Jerez de la Frontera Hosp. de Jerez de La Frontera	COMPLETED
Spain	Madrid Hosp. Univ. Ramon Y Cajal	COMPLETED
Spain	Pamplona Clinica Univ. de Navarra	COMPLETED
Spain	Santiago de Compostela Hosp. Clinico Univ. de Santiago	COMPLETED
Spain	Valladolid Hosp. Clinico Univ. de Valladolid	COMPLETED
United Kingdom	London University College Hospital	COMPLETED
United Kingdom	London Kings College Hospital	COMPLETED
United Kingdom	London St George's Hospital	COMPLETED
United Kingdom	Maidstone Maidstone Hospital	COMPLETED
United Kingdom	Surrey The Royal Marsden NHS Trust Sutton	COMPLETED
France	Lille CHRU de Lille Hopital Claude Huriez	COMPLETED
Austria	Wien Krankenhaus der barmherzigen Schwestern	RECRUITING
France	Montpellier Cedex 5 CHU de Montpellier Hopital Saint Eloi	COMPLETED
France	Toulouse cedex 9 Pôle IUC Oncopole CHU	COMPLETED
Germany	Karlsruhe Staedtisches Klinikum Karlsruhe gGmbH	RECRUITING
Germany	Leipzig MVZ Mitte-Onkologische Schwerpunktpraxis	RECRUITING
Italy	Bologna Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi	COMPLETED
Italy	Catania Policlinico di Catania	COMPLETED
Italy	Meldola Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	COMPLETED
Italy	Padova Universita degli Studi di Padova Azienda Ospedaliera di Pa	COMPLETED
Italy	Palermo Ospedale Villa Sofia-Cervello	COMPLETED
Italy	Pavia Fondazione IRCCS Policlinico San Matteo	COMPLETED
Italy	Roma Fondazione Policlinico Universitario A Gemelli IRCCS	COMPLETED
Spain	Gijón Hosp. de Cabuenes	RECRUITING
Spain	Leon Hosp. de Leon	RECRUITING
Spain	Madrid Hosp. Univ. 12 de Octubre	RECRUITING
Spain	Palma Hosp. Univ. Son Espases	RECRUITING
Spain	Salamanca Hosp Clinico Univ de Salamanca	RECRUITING
Spain	Santander Hosp. Univ. Marques de Valdecilla	RECRUITING
United Kingdom	Bristol Southmead Hospital	COMPLETED
United Kingdom	Nottingham Nottingham University Hospitals NHS Trust	COMPLETED
Austria	Leoben LKH Leoben	RECRUITING
Germany	Zwickau Heinrich-Braun-Klinikum gGmbH	RECRUITING
Greece	Alexandroupoli University Hospital of Alexandroupolis	RECRUITING
Greece	Athens Alexandra Hospital	RECRUITING
Greece	Thessaloniki Anticancer Hospital of Thessaloniki Theageneio	RECRUITING
Spain	Granada Hosp. Univ. Virgen de Las Nieves	RECRUITING
Spain	Valencia Hosp. Clinico Univ. de Valencia	RECRUITING
Spain	Valencia Hosp. Univ. Dr. Peset	RECRUITING

Geo Locations

50.87959, 4.70093

50.3279, 4.88059

47.21725, -1.55336

45.7009, 4.82511

52.4426272, 13.3103368

51.05089, 13.73832

53.57532, 10.01534

51.68033, 7.82089

49.40768, 8.69079

50.93333, 6.95

51.33962, 12.37129

48.52266, 9.05222

49.79391, 9.95121

41.11148, 16.8554

44.40478, 8.94438

41.89193, 12.51133

41.70643, 15.7277

39.93018, 18.35421

52.37403, 4.88969

53.21917, 6.56667

41.38879, 2.15899

36.68645, -6.13606

40.4165, -3.70256

42.81687, -1.64323

42.88052, -8.54569

41.65518, -4.72372

51.50853, -0.12574

51.26667, 0.51667

51.3434765, -0.1910896

50.63297, 3.05858

48.20849, 16.37208

43.61092, 3.87723

43.60426, 1.44367

49.00937, 8.40444

51.33962, 12.37129

44.49381, 11.33875

37.49223, 15.07041

44.12775, 12.0626

45.40797, 11.88586

38.13205, 13.33561

45.19205, 9.15917

41.89193, 12.51133

43.53573, -5.66152

42.60003, -5.57032

40.4165, -3.70256

39.56939, 2.65024

40.96882, -5.66388

43.46472, -3.80444

51.45523, -2.59665

52.9536, -1.15047

47.3765, 15.09144

50.72724, 12.48839

40.84995, 25.87644

37.97945, 23.71622

40.64361, 22.93086

37.18817, -3.60667

39.46975, -0.37739

Indicates 50+ sites in this region: click to zoom in.

Indicates 10+ sites in this region: click to zoom in.

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

OVERVIEW

Sexes Eligible for Study

Age

Phase

Sites

Status

SUMMARY

CONDITIONS

ELIGIBILITY

DETAILS

LOCATIONS

50.87959, 4.70093

50.3279, 4.88059

47.21725, -1.55336

45.7009, 4.82511

52.4426272, 13.3103368

51.05089, 13.73832

53.57532, 10.01534

51.68033, 7.82089

49.40768, 8.69079

50.93333, 6.95

51.33962, 12.37129

48.52266, 9.05222

49.79391, 9.95121

41.11148, 16.8554

44.40478, 8.94438

41.89193, 12.51133

41.70643, 15.7277

39.93018, 18.35421

52.37403, 4.88969

53.21917, 6.56667

41.38879, 2.15899

36.68645, -6.13606

40.4165, -3.70256

42.81687, -1.64323

42.88052, -8.54569

41.65518, -4.72372

51.50853, -0.12574

51.50853, -0.12574

51.50853, -0.12574

51.26667, 0.51667

51.3434765, -0.1910896

50.63297, 3.05858

48.20849, 16.37208

43.61092, 3.87723

43.60426, 1.44367

49.00937, 8.40444

51.33962, 12.37129

44.49381, 11.33875

37.49223, 15.07041

44.12775, 12.0626

45.40797, 11.88586

38.13205, 13.33561

45.19205, 9.15917

41.89193, 12.51133

43.53573, -5.66152

42.60003, -5.57032

40.4165, -3.70256

39.56939, 2.65024

40.96882, -5.66388

43.46472, -3.80444

51.45523, -2.59665

52.9536, -1.15047

47.3765, 15.09144

50.72724, 12.48839

40.84995, 25.87644

37.97945, 23.71622

40.64361, 22.93086

37.18817, -3.60667

39.46975, -0.37739

39.46975, -0.37739

Interested in participating?

Confirm